Subsidiaries Silence EContact Us>
Silence Therapeutics Silence Therapeutics
▲
170.00p (+1.00p)
Vol: 15000
(15-minute delayed)
View full stock quote


  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi Hub
  • Menu
  • About Us
    • Overview
    • Strategy
    • History
    • Management
    • Board Of Directors
    • Scientific Advisory Board
    • Careers
  • RNAI Platform
    • Overview
    • Delivery Platform
    • RNAi Platform
    • RNA Interference
    • Intellectual Property
    • Publications
    • Glossary
  • Pipeline
    • Overview
    • Pre-Clinical development
  • Collaborations
    • Overview
    • Silence's Strengths
    • Partnerships
    • Partnering Opportunities
  • Investor Relations
    • Overview
    • Press Releases
    • Reports and Disclosures
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Publications
  • RNAi Hub
  • Contact
 
 
News Events
Publications Companies
Clinical Trials  

Tag Archives: Cancer Res

Post navigation

← Older posts
  • Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.

    0 Replies

    June 01, 2013

    Related Articles Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res. 2013 May 29; Authors: Natsume A, Ito M, Katsushima K, Ohka F, Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I, Shimogawa H, Uesugi M, Okano H, Kim SU, Wakabayashi T,... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.

    0 Replies

    May 25, 2013

    c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res. 2013 May 23; Authors: Fan P, Griffith OL, Agboke F, Anur P, Zou X, McDaniel RE, Creswell K, Kim SH, Katzenellenbogen JA, Gray JW, Jordan VC Abstract The emergence of antiestrogen resistance in breast cancer is an... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • RXRα Inhibits the NRF2-ARE Signalling Pathway Through A Direct Interaction With the Neh7 domain of NRF2.

    0 Replies

    April 25, 2013

    RXRα Inhibits the NRF2-ARE Signalling Pathway Through A Direct Interaction With the Neh7 domain of NRF2. Cancer Res. 2013 Apr 23; Authors: Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li Y, Luo L, Hayes JD, Wang XJ, Tang X Abstract The transcription factor... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1.

    0 Replies

    April 16, 2013

    Related Articles Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1. Cancer Res. 2013 Apr 12; Authors: Cen B, Mahajan S, Wang W, Kraft AS Abstract The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult.... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer.

    0 Replies

    April 13, 2013

    Related Articles Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013 Apr 10; Authors: Bai ZF, Tai Y, Li W, Zhen C, Gu W, Jian Z, Wang Q, Lin JE, Zhao Q, Gong W, Liang B, Wang C, Zhou T Abstract Hepatic metastasis is responsible for... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • DOG1 regulates growth and IGFBF5 in gastrointestinal stromal tumors.

    0 Replies

    Related Articles DOG1 regulates growth and IGFBF5 in gastrointestinal stromal tumors. Cancer Res. 2013 Apr 10; Authors: Simon S, Grabellus F, Ferrera L, Galietta LJ, Schwindenhammer B, Muehlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S Abstract Gastrointestinal stromal tumors (GIST)... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

    0 Replies

    April 04, 2013

    Related Articles ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013 Apr 2; Authors: Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM Abstract Replication stress and DNA damage activate the ATR-CHK1 checkpoint signaling pathway that licenses... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein.

    0 Replies

    March 08, 2013

    Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein. Cancer Res. 2013 Mar 6; Authors: Dua P, Kang HS, Hong SM, Tsao MS, Kim S, Lee DK Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very low median survival rate. The lack of early sensitive diagnostic... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer.

    0 Replies

    February 20, 2013

    CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res. 2013 Feb 15; Authors: Du L, Rao G, Wang H, Li B, Tian W, Cui JT, He L, Laffin B, Tian X, Hao C, Liu H, Sun X, Zhu Y, Tang DG, Mehrpour... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 
  • Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

    0 Replies

    February 14, 2013

    Related Articles Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res. 2013 Feb 11; Authors: Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I Abstract STAT5... Contine Reading & Discuss→

    Posted in :  News |  Other News |  Publications |  Syndicated |  Tagged in :  Cancer Res | 

Post navigation

← Older posts

Sign up to receive alerts

>

Submit

ARCHIVES

Open

2013

  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
Open

2012

  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
Open

2011

  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
Open

2010

  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
Open

2009

  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
Open

2008

  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
Open

2007

  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
Open

2006

  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
Open

2005

  • December 2005
  • November 2005
  • August 2005
  • July 2005
  • June 2005
  • May 2005
  • April 2005
  • March 2005
  • February 2005
  • January 2005
Open

2004

  • October 2004
  • July 2004
  • June 2004
Open

2003

  • December 2003
  • May 2003

TAGS

Arrowhead Research Corporation Biochem Biophys Res Commun Biochim Biophys Acta Biomaterials Blood BMC Genomics BMC Plant Biol cancer Cancer Res Cell Curr Biol Dev Biol Genes Dev Genetics Industry News Insect Biochem Mol Biol Int J Oncol J Biol Chem J Cell Sci J Virol Mariana Bio Methods Mol Biol microRNA Micro RNA Blog Mirapharm mirna Mol Biol Cell Mol Biol Rep Mol Cell Biol Mol Ther Mol Ther Nucleic Acids Nucleic Acids Res Oncol Rep Plant Biotechnol J Plant Physiol PLoS Genet PLoS One PLoS Pathog Proc Natl Acad Sci U S A Report Report Linker RNAi Santaris silence therapeutics Uncategorized

Quick Links

  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi HUB
  • Site Map

Contact

3 Shortlands
Hammersmith
London W6 8DA
United Kingdom


Tel:+44 (0) 333 9880 140
Fax:+44 (0) 795 731 8494
Silence Therapeutics

Copyright © 2013 Silence Therapeutics.
All rights reserved.

Terms of Use
Forward-Looking Statement